EQS-News

Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock

EQS-News: RELIEF THERAPEUTICS Holding AG / Key word(s): Personnel Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock 02.02.2022 / 07:00 Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock

Industry Executive Brings Nearly 30 Years of Biopharmaceutical Sales and Commercial Expertise

Geneva, Switzerland, February 2, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that, as approved and reported after its January 28, 2022 extraordinary general meeting, Michelle Lock, Chief Operating Officer of Covis Pharma Group, has been appointed to the company's Board of Directors. The appointment brings Relief's Board to five members.

"Michelle's deep strategic, operational and commercialization experience, at both big Pharma and emerging biotechnology companies, globally, will be an important addition to our Board, especially as we enter our next stage of company growth," stated Raghuram (Ram) Selvaraju, Chairman of Relief. "In particular, we look forward to leveraging Michelle's breadth of expertise and industry relationships garnered from her tenures at Acceleron Pharma, Sage Therapeutics and Bristol-Myers Squibb, as we advance our pipeline including, RLF-100(TM) for acute and chronic lung diseases, the prospective launch of ACER-001 to treat Urea Cycle Disorders later this year, and the expansion of the flagship PKU GOLIKE(R) marketed product line for management of patients with phenylketonuria."

"Relief's suite of commercial stage biopharmaceuticals, along with an impressive product pipeline and highly focused growth strategy, was instrumental in my decision to join the company's Board," noted Ms. Lock. "I am delighted to contribute my insights and experience to Relief to help management achieve its U.S. and international commercialization goals at this pivotal time in the company's history."

Ms. Lock's broad biopharmaceutical industry experience spans nearly 30 years and includes leadership roles in commercialization across various therapeutic areas including oncology, hematology, cardiovascular and metabolic disease, liver disease, immunology, virology and neuroscience. Additionally, her experience includes oversight of pre-launch and launch commercial activities in multiple geographies, including the U.S., Europe, Japan, Australia, Asia, and emerging markets.